bit.bio
bit.bio is an award-winning human synthetic biology company whose mission is to code cells for novel cures. They have developed an end-to-end platform for the creation of any human cell type. With their cutting-edge and patent-protected opti-ox™ precision cell programing technology, bit.bio can deterministically program human induced pluripotent stem cells (iPSCs) into a chosen cell identity with unprecedented biological consistency at an industrial scale and approximately 10 times faster than conventional methods. Their platform has the potential to unlock a new generation of medicines.
Latest bit.bio Content
Webinar
Precision Cellular Reprogramming for Scalable and Consistent Human Neurodegenerative Disease Models
On-Demand
bit.bio’s first-of-its-kind precision cellular reprogramming technology, opti-ox™, addresses the limitations of lot consistency, cell definition and scalability by controlling the precise expression of cell-fate determining genetic factors.
How To Guide
Four Hacks for Culturing Neurons
Human iPSC-derived excitatory neurons provide helpful physiologically relevant cell models to investigate neurodevelopmental and neurodegenerative disorders, although achieving healthy neuronal cultures can be challenging.
Poster
Modeling Neurodegeneration Using a Human Isogenic System
Patient-derived induced pluripotent stem cells (iPSCs) enable generation of in vitro models that can recapitulate human disease phenotypes. However, conventional human iPSC differentiation protocols are often lengthy, inconsistent and difficult to scale.
Poster
Modeling Neurodegeneration: A Next-Generation Approach To Study Huntington’s Disease
To overcome these challenges, researchers have developed a proprietary gene-expression targeting strategy that can rapidly reprogram hiPSCs into pure somatic cell types in a scalable manner. This approach was used to develop a Huntington’s disease (HD) model carrying a 50CAG expansion in the huntingtin (HTT) gene.
Webinar
Rethinking Developmental Biology With Cellular Reprogramming
On-Demand
In this webinar, Professor Marius Wernig from Stanford University and Dr. Mark Kotter, CEO and founder of bit.bio offer an expert discussion on the pioneering research of cell reprogramming.
Product
Advertisement
ioGABAergic Neurons – iPSC-Derived Inhibitory Neurons With >95% Purity
Discover ioGABAergic Neurons from bit.bio and avoid unwanted excitatory neurons obscuring inhibitory signals in your experiments. Using a simple protocol, consistently go from cryopreserved cells to mature, functional, experiment-ready hiPSC-derived GABAergic neurons with >95% purity in 12 days.
App Note / Case Study
Developing Next-Generation In Vitro Phenotypic Assays for Huntington’s Disease
There is currently no effective cure or treatment to slow down or stop the progression of Huntington's disease (HD). One reason for this is the lack of accurate and easy-to-use HD models.
Webinar
Alzheimer's Disease Pathogenesis: Emerging Role of Microglia
On-Demand
Alzheimer’s disease is the most common form of neurodegenerative disease, estimated to contribute to 60–70% of all cases of dementia worldwide. Increasing evidence suggests that neuroinflammation, primarily mediated by microglia, contributes to the onset and progression of Alzheimer’s disease.
Product
Advertisement
ioMicroglia™ – Consistent iPSC-Derived Microglia, Ready in 10 Days!
Discover ioMicroglia from bit.bio – human iPSC-derived microglia that are consistent, co-culture compatible and ready for experimentation in just 10 days. Limited early access vials are available now. Register your interest today.
Product News
bit.bio Adds Two New Human Cell Products To Accelerate Research and Drug Discovery for Neurodegenerative Disease
Cell coding company bit.bio has announced an expansion to its product portfolio to enable scientists to study neurodegenerative diseases in a human context.
Advertisement
